The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
COVID-19 Infection Could Increase Risk of Developing Diabetes
July 19th 2022An analysis of data from more than 450,000 patients in the UK details an 81% increase in the net incidence of diabetes in the first 4 weeks after contracting COVID-19, which remained elevated through weeks 5-12, compared to those who did not contract COVID-19.
Increased Physical Activity Linked to Lower Cardiovascular Risk in Chronic Kidney Disease
July 13th 2022An analysis of patients with CKD from the CRIC study demonstrates those with the highest levels of physical activity had reductions in risk of 36%, 29%, and 53% for atherosclerotic events, incident heart failure, and cardiovascular mortality, respectively, compared to those with the lowest levels.
Cardiometabolic Decisions and Trials to Watch for Second Half of 2022
July 8th 2022After highlighting the first half of the year in our top decisions from the first half of 2022, Practical Cardiology’s editorial staff fixed its gaze on the cardiology pipeline for the remainder of 2022. In this list, we highlight potential FDA Decisions and trials to watch for in the second half of the year.
Top FDA Decisions in Cardiometabolic Health from the First Half of 2022
July 1st 2022The first half of 2022 has seen its fair share of FDA decisions, both approvals and CRLs. In this article, we recap the top regulatory events in cardiorenal metabolic health from the first half of the year, including news related to empagliflozin, mavacamten, and more.
Using AHA's Essential 8, New Study Details Need for Optimized Cardiovascular Health in US
June 30th 2022New research from the first study to use the AHA's Life's Essential 8 to assess cardiovascular health at a population level details the lack of optimized cardiovascular health among adults and children in the US.
American Heart Association Debuts Life's Essential 8, Adds Sleep to Life's Simple 7
June 29th 2022On June 29, the American Heart Association announced Life's Simple 7 is a thing of the past and will now include a section dedicated to the impact of sleep on cardiovascular health with the debut of Life's Essential 8.